Latest Retigabine Stories
Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store.
LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
An epilepsy drug shows promise in an animal model at preventing tinnitus from developing after exposure to loud noise.
LONDON and MISSISSAUGA, Ontario, March 29, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc.
MAPLE GROVE, Minn., Nov. 9, 2010 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the addition of an open-label extension study to PREVAIL, its global Phase III clinical trial for USL255 (extended-release topiramate).
Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS).
RESEARCH TRIANGLE PARK, N.C. and ALISO VIEJO, Calif., Aug. 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today that a U.S.
ALISO VIEJO, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that the U.S.
ALISO VIEJO, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today provided the following update on the regulatory applications to the U.S.
- New antiepileptic drug with novel mechanism of action helps address critical unmet medical need for many people living with uncontrolled epilepsy - Vimpat(R) offers hope to people with epilepsy who still have uncontrolled partial onset seizures with current treatment ATLANTA, May 26 /PRNewswire/ -- press release, regulated information - UCB today announced that Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED) is available in the U.S.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.